SecBot SecBot
DEFA14A ·Filed Apr 24, 2026

CRVS

Corvus Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonimmediate Processed6mo ago SEC0001104659-26-048600
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the outcome of the director election and auditor ratification as standard governance items. The non-binding vote on executive compensation provides insight into shareholder sentiment but does not mandate any financial changes.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.92
T+0 close · Apr 24, 2026 · via day close
Latest settled
−12.12%
T+60 · $13.99
Vs SPY
−16.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $15.92entry
  2. T+1 · 7mo ago −1.88%α −1.40% · $15.62
  3. T+5 · 7mo ago +0.63%α +0.23% · $16.02
  4. T+20 · 6mo ago −19.41%α −24.37% · $12.83
  5. T+60 · 4mo ago −12.12%α −16.90% · $13.99
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Corvus Pharmaceuticals filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, which includes proposals to elect two Class I Directors, ratify the selection of PricewaterhouseCoopers LLP as the independent auditor, and approve the compensation of named executive officers. This filing follows the recent appointment of Dr. Andrew Chan to the board and the resignation of Scott Morrison, indicating board changes near the proxy materials. The vote is non-binding on executive compensation.

Key Financial Metrics

Vote
director election
Meeting
2026-06-11
Seats Contested
2

Key Facts

  • The proxy statement is for the 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026.
  • Proposals include the election of two Class I Directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of named executive officer compensation.
  • The board recommends a vote FOR all proposals.
  • This filing follows an 8-K filing on April 23, 2026, which announced the appointment of Dr. Andrew Chan to the board and the resignation of Scott Morrison.
  • The vote on executive compensation is non-binding.

Financial Impact

No direct financial impact from the vote itself. The ratification of the auditor and director elections are standard governance actions. The compensation approval is non-binding.

governanceboard compositionauditorexecutive compensation

Risk Factors

  • Failure to ratify the auditor could lead to a restatement or audit issues.
  • A significant vote against executive compensation could signal shareholder dissatisfaction, potentially impacting executive retention or company reputation.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-048600
Document: 0001104659-26-048600-index-headers.html0001104659-26-048600
Document: 0001104659-26-048600-index.html0001104659-26-048600
Document: 0001104659-26-048600.txt0001104659-26-048600

Track record

15 reports on CRVS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
  4. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  5. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
  6. Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
  7. Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
  8. Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
  10. May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026